📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. (2019)

First Author: Haynes R

Attributed to: Randomised trials in cardiovascular and metabolic disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.clinthera.2019.06.012

PubMed Identifier: 31447131

Publication URI: http://europepmc.org/abstract/MED/31447131

Type: Journal Article/Review

Volume: 41

Parent Publication: Clinical therapeutics

Issue: 9

ISSN: 0149-2918